Denosumab approved in Europe for treatment of SREs

Denosumab (Xgeva®) has been approved by the European Medicines Agency (EMEA) for the prevention of skeletal-related events (SREs) in adults with bone metastases from solid tumors, including prostate cancer, according to a media release issued by Amgen last Friday. … READ MORE …

European clinical trials register finally goes live

The European Medicines Agency (EMA) has announced the launch of the EU Clinical Trials Register. This trial register will allow residents of the 27 EU member states, as well as Iceland, Liechtenstein, and Norway, to more easily find data about clinical trials of therapies for the management of prostate cancer (including new drugs). … READ MORE …

European Medicines Agency approves cabazitaxel

According to a media release from Sanofi-Aventis and a report on the Reuters web site today, the European Medicines Agency (EMEA) has approved cabazitaxel (Jevtana) … READ MORE …

Incidence and mortality rates in 37 European countries

A new analysis by the International Agency for Research on Cancer offers an update on the incidence and mortality rates associated with prostate cancer in Europe over the past 20 years. … READ MORE …

New European guidelines on clinically localized prostate cancer

The European Association of Urology (EAU) has issued updated guidelines on the screening, diagnosis, and treatment of clinically localized prostate cancer. … READ MORE …

Management of T3 prostate cancer in Europe

The gold standard treatment for clinical stage T3 prostate cancer has long been the combination of radiotherapy and extended hormone therapy. However, the accuracy of clinical staging based on DRE is open to some question, since 20 percent of patients assessed to have cT3 prostate cancer today appear to be over-staged during physical examination. … READ MORE …

Your weekend news reports: April 4, 2009

The three reports in today’s news cover:

  • A future perspective on treatments for localized disease
  • Robot-assisted laparoscopic prostatectomy in Europe
  • Long-term follow-up on urinary toxicities following brachytherapy … READ MORE …